RxDoctor Payments Data

Robert Spees, MD

Internal Medicine · Colorado Springs, CONPI 1154419281

Payments from drug & device makers

$2,733in general payments, 2019–2025

Across 136 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tris Pharma Inc$240
  • Novo Nordisk$230
  • Ironshore Pharmaceuticals Inc.$206
  • Otsuka America Pharmaceutical, Inc.$205
  • Amgen$197
  • AstraZeneca$197
  • plus $1K from 36 others

What the payments were for

  • Speaking & faculty fees$221%
  • Food & beverage$2,70399%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,733 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$113,492
Medicare patients
229
Services billed
1,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$75,165
XareltoRivaroxaban25$28,312
OzempicSemaglutide18$25,865
JanuviaSitagliptin Phosphate16$24,913
JardianceEmpagliflozin15$23,224
GemtesaVibegron16$12,465
JanumetSitagliptin Phos/Metformin Hcl12$8,889
Spiriva HandihalerTiotropium Bromide11$5,594
Arnuity ElliptaFluticasone Furoate12$2,421
Levothyroxine Sodium272$2,305
Rosuvastatin Calcium258$2,298
Omeprazole114$1,730
Tizanidine Hcl37$1,584
Atorvastatin Calcium204$1,396
Gabapentin79$1,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$75,16559 claims
Johnson & JohnsonXarelto$26$28,31225 claims
Novo NordiskOzempic$230$25,86518 claims
Boehringer IngelheimJardiance$85$23,22415 claims
Sumitomo Pharma America, Inc.Gemtesa$25$12,46516 claims
GSKArnuity Ellipta$65$2,42112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →